Drug Safety

Do Biological Medicinal Products Pose a Risk to the Environment?: A Current View on Ecopharmacovigilance
pp. 995-1000(6)
Authors: Kühler, Thomas C.; Andersson, Mikael; Carlin, Gunnar; Johnsson, Ann; Åkerblom, Lennart

A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
pp. 1001-1015(15)
Authors: Wolf, Dominik; Rumpold, Holger

Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies
pp. 1017-1039(23)
Authors: Caccia, Silvio; Garattini, Silvio; Pasina, Luca; Nobili, Alessandro

Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials: A Systematic Review and Meta-Analysis
pp. 1041-1056(16)
Authors: Rief, Winfried; Nestoriuc, Yvonne; >Anna von Lilienfeld-Toal,; Dogan, Imis; Schreiber, Franziska; Hofmann, Stefan G.; Barsky, Arthur J.; Avorn, Jerry

Risk Management Policy and Black-Box Warnings: A Qualitative Analysis of US FDA Proceedings
pp. 1057-1066(10)
Authors: Cook, Daniel M.; Gurugubelli, Rama K.; Bero, Lisa A.

Consumer Reporting of Adverse Drug Reactions: A Retrospective Analysis of the Danish Adverse Drug Reaction Database from 2004 to 2006
pp. 1067-1074(8)
Authors: Aagaard, Lise; >Lars Hougaard Nielsen,; >Ebba Holme Hansen,

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs: An Interrupted Time-Series Analysis in Spain
pp. 1075-1087(13)
Authors: Sanfélix-Gimeno, Gabriel; Cervera-Casino, Pedro; Peiró, Salvador; López-Valcarcel, Beatriz González; Blázquez, Amparo; Barbera, Teresa

Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment: A Retrospective Cohort Study of Children, Adolescents and Young Adults Using the General Practice Research Database
pp. 1089-1096(8)
Authors: McCarthy, Suzanne; Cranswick, Noel; Potts, Laura; Taylor, Eric; Wong, Ian C.K.

Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Sudden Death
pp. 1097-1100(4)
Author: Besag, Frank M.C.